Akebia Therapeutics Receivables

Akebia Therapeutics (AKBA) currently reports a receivables of $54M as of June 2026. That compares with $73M in the prior-year period — down 26.5% year over year. Use the charts on this page to explore Akebia Therapeutics's receivables history and peer comparisons.

Akebia Therapeutics's receivables decreased from $73M to $54M — a 26.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Akebia Therapeutics reported $54M in receivables as of June 2026. That compares with $73M in the prior-year period — down 26.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $54M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Akebia Therapeutics, and consider following AKBA for alerts when major investors trade the stock.

Akebia Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $54M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AKBA with unrelated industries.